UPDATE: JPMorgan Downgrades bluebird bio (BLUE) to Neutral

February 17, 2021 4:33 AM EST
Get Alerts BLUE Hot Sheet
Price: $28.02 -0.36%

Rating Summary:
    15 Buy, 14 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 18 | Down: 10 | New: 12
Trade Now! 
Join SI Premium – FREE
(Updated - February 17, 2021 4:54 AM EST)

JPMorgan analyst Cory Kasimov downgraded bluebird bio (NASDAQ: BLUE) from Overweight to Neutral with a price target of $39.00 (from $76.00).

The analyst comments "In our view, there’s still a reasonably good chance that BLUE secures approval for its first three products under development for four indications (LentiGlobin in TDT and SCD, bb2121 in MM, and Lenti-D in CCALD). LentiGlobin's fate, however, is now highly tied to the investigation of recent cases of AML and MDS in previously treated patients. The company also has multiple novel platform capabilities –
gene therapy, gene editing, and CAR-T among them – that could help to restock the pipeline over time."

For an analyst ratings summary and ratings history on bluebird bio click here. For more ratings news on bluebird bio click here.

Shares of bluebird bio closed at $28.44 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, Downgrades

Related Entities

JPMorgan